These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23842688)

  • 21. Danshen Gegen capsule for intermittent claudication in patients with peripheral arterial disease: abridged secondary publication.
    Yan BPY; Fung KP; Chook P; Koon JCM; Chan JYW
    Hong Kong Med J; 2021 Jun; 27 Suppl 2(3):11-13. PubMed ID: 34075884
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
    Hiatt WR; Creager MA; Amato A; Brass EP
    J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ramipril on arterial stiffness.
    O'Rourke MF; Nichols WW; O'Brien E
    Hypertension; 2005 Oct; 46(4):e14; author reply e14-5. PubMed ID: 16195488
    [No Abstract]   [Full Text] [Related]  

  • 24. Medical management of claudication.
    Ratchford EV
    J Vasc Surg; 2017 Jul; 66(1):275-280. PubMed ID: 28533077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ramipril on postrevascularization prevalence of angina and quality of life.
    Kjøller-Hansen L; Steffensen R; Grande P
    Int J Cardiol; 2004 Jun; 95(2-3):159-65. PubMed ID: 15193814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Management of patients with intermittent claudication].
    Fiessinger JN; Sapoval M; Julia P
    Rev Prat; 2005 Jun; 55(11):1190-2, 1195-7. PubMed ID: 16164064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture.
    Ahimastos AA; Natoli AK; Lawler A; Blombery PA; Kingwell BA
    Hypertension; 2005 Jun; 45(6):1194-9. PubMed ID: 15897362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin converting enzyme inhibitors and walking distance: Have we walked the whole distance?
    Vlachopoulos C; Terentes-Printzios D; Aboyans V; Brodmann M; De Carlo M; Tousoulis D
    Atherosclerosis; 2016 Sep; 252():199-200. PubMed ID: 27543007
    [No Abstract]   [Full Text] [Related]  

  • 30. Ramipril: the better angiotensin-converting enzyme inhibitor?
    Gupta R
    Indian Heart J; 2008; 60(3):188-91. PubMed ID: 19240304
    [No Abstract]   [Full Text] [Related]  

  • 31. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".
    Popa C; Netea MG
    Circulation; 2008 Nov; 118(19):e690; author reply e691. PubMed ID: 18981309
    [No Abstract]   [Full Text] [Related]  

  • 33. Improvement in symptoms of peripheral arterial disease with sildenafil therapy.
    Turtle EJ; Drummond ID; Webb DJ
    Scott Med J; 2013 Aug; 58(3):e7-9. PubMed ID: 23960069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
    Anderson VR; Perry CM; Robinson DM
    Am J Cardiovasc Drugs; 2006; 6(6):417-32. PubMed ID: 17192135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].
    Karakin AA; Khrustalev OA; Bol'shakova MA; Forsilov VE
    Ter Arkh; 1996; 68(2):43-6. PubMed ID: 8771657
    [No Abstract]   [Full Text] [Related]  

  • 36. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
    Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
    J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.
    Olson E; Demopoulos L; Haws TF; Hu E; Fang Z; Mahar KM; Qin P; Lepore J; Bauer TA; Hiatt WR
    Vasc Med; 2014 Dec; 19(6):473-82. PubMed ID: 25377872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral arterial disease.
    Hiatt WR; Nehler MR
    Adv Intern Med; 2001; 47():89-110. PubMed ID: 11795081
    [No Abstract]   [Full Text] [Related]  

  • 39. [Comparative assessment of antihypertensive effects of angiotensin-converting enzyme inhibitors ramipril and captopril in patients with hypertension in ambulatory settings].
    Lebedev AV; Kukushkin SK; Manoshkina EM; Shamarin VM; Deev AD
    Kardiologiia; 2003; 43(3):71-2. PubMed ID: 12913982
    [No Abstract]   [Full Text] [Related]  

  • 40. Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery.
    Hasija S; Makhija N; Choudhury M; Hote M; Chauhan S; Kiran U
    J Cardiothorac Vasc Anesth; 2010 Apr; 24(2):230-8. PubMed ID: 19875309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.